MaesTTRo
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
Sponsor study identifier
observational
1,850
6 countries
89
Study Start
June 25, 2024
Actual (reported)Primary Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 13, 2024
Actual (reported)June 20, 2024
Actual (reported)June 25, 2024
Actual (reported)December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Demographic characteristics (overall and in patients initiating a treatment with eplontersen)
* Age * Sex as determined by the investigator (male/female) * Race and ethnicity, where allowed
From time of enrollment for up to 7 years
Treatment patterns (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following treatments will be assessed: * ATTR amyloidosis treatment: Tafamidis, Diflunisal, Acoramidis, Vutrisiran, Patisiran, Inotersen, Eplontersen, Doxycycline and taurodesoxycholic acid, Liver transplant * Heart failure/arrhythmia-related treatment: Diuretics, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Angiotensin receptor-neprilysin inhibitor, Anticoagulation, Beta-blockers, Sodium-glucose co-transporter-2 inhibitor, Mineralocorticoid receptor antagonist, Digoxin, Pacemaker use, Implantable cardioverter-defibrillator, Left ventricular assist device, Cardiac transplant, Transcatheter aortic valve replacement, Surgical aortic valve replacement * Polyneuropathy-related treatment: Antiepileptics (gabapentin, pregabalin, carbamazepine, phenytoin), Antidepressants, Topical pain treatments, Opioids, Tetrahydrocannabinol * Other: Medications for gastrointestinal symptoms, Vitamin A supplementation, Dialysis
Patients with ATTR-CM at enrollment
Patients with ATTRv-PN at enrollment
Patients with a mixed ATTR amyloidosis phenotype
Data will be collected on patients with ATTR amyloidosis in a real-world setting
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with a diagnosis of amyloid transthyretin (ATTR) amyloidosis
Research Site
La Jolla, California, 92037, United States
Research Site
Los Angeles, California, 90095, United States
Research Site
San Francisco, California, 94025, United States
Research Site
San Francisco, California, 94143, United States
Gillmore JD, Hahn K, Smith JG, Conceicao I, Tian Z, Grogan M, Pao C, Wittbrodt E, Jarbrink K, Papas MA, Davis MK. Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care. Cardiol Ther. 2025 Sep;14(3):477-490. doi: 10.1007/s40119-025-00402-y. Epub 2025 Mar 19.
AstraZeneca Clinical Study Information Center
CONTACT
First Submitted
May 13, 2024
First Posted
June 20, 2024
Study Start
June 25, 2024
Actual (reported)Primary Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
From time of enrollment for up to 7 years
Clinical characteristics (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following clinical characteristics will be assessed: * Modified body mass index (mBMI) * Medical history * TTR genetic test results * Family history of ATTR * Time period between the first symptoms to date of diagnosis of ATTR * Time since diagnosis of ATTR
From time of enrollment for up to 7 years
Findings from biopsy (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following biopsy information will be collected: * Type of biopsy * Amyloid identification result (Positive, Negative, Inconclusive for amyloid) * Method of amyloid typing * Result of the biopsy (Normal/Abnormal) * Reason for considering the biopsy result abnormal
From time of enrollment for up to 7 years
Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: extracellular volume (ECV), contrast use, left ventricular (LV) end-diastolic volume, LV end-systolic volume, LV ejection fraction, LV Mass Index, interventricular wall thickness, right ventricular Free Wall Thickness, LV Free Wall Thickness, left Atrial Volume Index, native T1 mapping, CMR result (Normal/Abnormal), reason for considering the result abnormal.
From time of enrollment for up to 7 years
Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: Type of tracer, Heart to contralateral lung ratio (H/CL), Perugini grade, scintigraphy result (Normal/Abnormal), reason for considering the result abnormal.
From time of enrollment for up to 7 years
Findings from Echocardiography (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: LV ejection fraction, LV End Diastolic Volume, LV End Systolic Volume LV End Diastolic Dimension, LV End Systolic Dimension, Interventricular Septal Thickness End Diastole, Posterial Wall Thickness End Diastole, Left Ventricular Mass Index, Left Atrial Volume, Left Atrial Volume Index, Mitral valve regurgitation, Aortic valve regurgitation, Tricuspid valve regurgitation, Pulmonic valve regurgitation, LV Outflow Gradient, Stroke Volume, Lateral early diastolic myocardial velocity (e' lateral), Medial early diastolic myocardial velocity (e' medial), Mitral E/e' Ratio, Early diastolic mitral inflow velocity (E), Late diastolic mitral inflow velocity (A), Mitral Peak E/A Ratio, Global LV longitudinal strain, Pulmonary artery systolic pressure, RV Free Wall Thickness Severity of Aortic stenosis, Severity of Mitral stenosis.
From time of enrollment for up to 7 years
ECG variables (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following ECG information will be collected: * Interpretation of the ECG (Normal/Abnormal/Borderline) * Heart rhythm * Presence of extrasystoles * Presence of conduction abnormalities * Evidence of left ventricular hypertrophy (LVH)
From time of enrollment for up to 7 years
Sural nerve and tibial nerve amplitude (overall and in patients initiating a treatment with eplontersen)
Sural nerve and tibial nerve amplitude will be measured in overall and in patients initiating a treatment with eplontersen
From time of enrollment for up to 7 years
Biomarker results (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following biomarker results will be collected: * Serum TTR levels * Complete blood count * Hemoglobin * Troponin I * Cystatin * Creatinine * Reported glomerular filtration rate (GFR) * Albumin * Liver enzymes: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), total bilirubin * N-terminal pro B-type natriuretic peptide (NT-proBNP) * Vitamin A level * Neurofilament light chain (NfL) * International normalized ratio (INR) test
From time of enrollment for up to 7 years
Urine test results (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following test results will be collected: * Urine albumin-creatinine ratio (UACR) * Urine protein creatinine ratio (UPCR)
From time of enrollment for up to 7 years
Clinical manifestations (signs and symptoms) of ATTR amyloidosis (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following clinical manifestations will be assessed: ischemic heart disease, acute myocardial infarction, heart failure, atrial fibrillation, arrhythmias, conduction system disease, aortic valve stenosis polyneuropathy, carpal tunnel syndrome, autonomic neuropathy, nephrotic syndrome, subnephrotic proteinuria, gastrointestinal dysfunction, chronic kidney disease / acute kidney injury, spinal stenosis, spinal stenosis surgery, hepatomegaly, ascites, oedema, other amyloidosis related manifestations (e.g., Popeye's sign, tendon rupture)
From time of enrollment for up to 7 years
36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score (overall and in patients initiating a treatment with eplontersen)
The SF-36v2 is a 36-item, generic health survey that provides scores for eight health domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores; the physical component summary (PCS) score and the mental component summary (MCS) score. Higher scores indicate a better health state.
From time of enrollment for up to 7 years
Norfolk Quality of Life-Diabetic Neuropathy total score (overall and in patients initiating a treatment with eplontersen)
The Norfolk QOL-DN is a 35-item, disease-specific instrument that provides scores for five domains (symptoms, large fiber neuropathy, small fiber neuropathy, autonomic neuropathy, and activities of daily living) and a total score. Higher scores indicate a worse health state.
From time of enrollment for up to 7 years
Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (overall and in patients initiating a treatment with eplontersen)
The KCCQ is a 23-item, disease-specific questionnaire that assesses seven domains (physical limitations, symptom stability, symptom frequency, symptom burden, self-efficacy, quality of life, and social limitation) and provides three summary scores (total symptom score, clinical summary score, and overall summary score). Higher scores indicate a better health state.
From time of enrollment for up to 7 years
New York Heart Association (NYHA) classification (overall and in patients initiating a treatment with eplontersen)
I=No symptoms; II=Symptoms with ordinary physical activity; III=Symptoms with less than ordinary physical activity; IV=Symptoms at rest.
From time of enrollment for up to 7 years
National Amyloidosis Centre (NAC) ATTR staging or Mayo staging (overall and in patients initiating a treatment with eplontersen)
For NAC staging, Stage I: N-terminal pro-brain natriuretic peptide (NT-proBNP) ≤3000 ng/L and estimated glomerular filtration rate (eGFR) ≥45 ml/min; Stage III: NT-proBNP \>3000 ng/L and eGFR \<45 ml/min; Stage IV:NT-proBNP ≥10,000 ng/L; Stage II: remainder of patients For Mayo staging, Stage I: Both and biomarker values are below the established thresholds; Stage II: Either troponin T or NT-proBNP is above the threshold; Stage III: Both troponin T and NT-proBNP biomarker values are above the threshold. Biomarker Thresholds: Troponin T: \>0.05 mg/mL and NT-proBNP: \>3000 pg/mL.
From time of enrollment for up to 7 years
Familial amyloid polyneuropathy (FAP) (Coutinho) staging (overall and in patients initiating a treatment with eplontersen)
Stage 0: No symptoms; Stage I: Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II: Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III: Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.
From time of enrollment for up to 7 years
Polyneuropathy disability (PND) score (overall and in patients initiating a treatment with eplontersen)
Stage 0=No symptoms; Stage I=Sensory disturbances but preserved walking capabilities; Stage II=Impaired walking capacity, but ability to walk without a stick or crutches; Stage IIIA=Walking with help of 1 stick or crutch; Stage IIIB=Walking with the help of 2 sticks or crutches; Stage IV=confined to wheel chair or bedridden.
From time of enrollment for up to 7 years
Left Ventricular Ejection Fraction (overall and in patients initiating a treatment with eplontersen)
Left Ventricular Ejection Fraction will be measured in overall and in patients initiating a treatment with eplontersen
From time of enrollment for up to 7 years
6-minute walk test (overall and in patients initiating a treatment with eplontersen)
To address this objective, the distance walked in 6 minutes will be measured.
From time of enrollment for up to 7 years
Charlson comorbidity index (CCI) and CCI components (overall and in patients initiating a treatment with eplontersen)
In order to address CCI, most recent score and all CCI componenet will be measured * Myocardial infarction * Congestive heart failure * Peripheral vascular disease * Cerebrovascular disease * Dementia * Chronic pulmonary disease * Rheumatic disease * Peptic ulcer disease * Diabetes (None, Without chronic complications, With chronic complications) * Hemiplegia or paraplegia * Renal disease * Any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin (None, Localized, Metastatic) * Liver disease (None, Mild, Moderate, Severe) * Metastatic solid tumor * Acquired immune deficiency syndrome (AIDS) / Human immunodeficiency virus (HIV)
From time of enrollment for up to 7 years
Other comorbidities of interest (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: * Percentage of patients with depression * Percentage of patients with fibromyalgia * Percentage of patients with paraproteinemia
From time of enrollment for up to 7 years
Healthcare resource utilization (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: * Number of emergency department visits * Number of outpatient visits * Inpatient care/hospitalization general ward (non-intensive): number of inpatient stays, number of bed days * Inpatient care/hospitalization intensive ward: number of inpatient stays, number of bed days
From time of enrollment for up to 7 years
Mortality (overall and in patients initiating a treatment with eplontersen)
Mortality during study follow-up (all-cause, related to ATTR amyloidosis), overall and by NYHA/NAC or Mayo/FAP stage
Throughout study follow-up (up to 7 years)
Liver Disease and Live Transplant
* Liver disease (for patients with mild, moderate or severe liver disease: Child Pugh score, Child Pugh class, ascites, encephalopathy) * Liver transplantation (reason for transplant, type of transplant)
From time of Enrollment for up to 7 Years
Comparison of demographic and clinical characteristics of patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Up to 7 years
Comparison of findings from biopsy in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Up to 7 years
Comparison of findings from Cardiovascular magnetic resonance imaging (CMR) in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Up to 7 years
Comparison of findings from Echocardiography in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Up to 7 years
Comparison of ECG variables of patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Up to 7 years
Risk factors for worsening ATTR progression
up to 7 years
Healthcare costs in patients with ATTR amyloidosis
Up to 7 years
Serious adverse events in patients treated with ATTR amyloidosis treatments
Up to 7 years
Contact the study team to confirm eligibility.
Research Site
New Haven, Connecticut, 06510, United States
Research Site
Washington D.C., District of Columbia, 20010, United States
Research Site
Chicago, Illinois, 60637, United States
Research Site
Indianapolis, Indiana, 06200, United States
Research Site
Baltimore, Maryland, 21218, United States
Research Site
Boston, Massachusetts, 02111, United States
Research Site
Boston, Massachusetts, 02114, United States
Research Site
Boston, Massachusetts, 02115, United States
Research Site
Rochester, Minnesota, 55905, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
St Louis, Missouri, 63110, United States
Research Site
New Brunswick, New Jersey, 08901, United States
Research Site
Manhasset, New York, 11030, United States
Research Site
New York, New York, 10016, United States
Research Site
New York, New York, 10027, United States
Research Site
New York, New York, 10029, United States
Research Site
Durham, North Carolina, 27710, United States
Research Site
Portland, Oregon, 97239, United States
Research Site
Danville, Pennsylvania, 17822, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Philadelphia, Pennsylvania, 19107, United States
Research Site
Greenville, South Carolina, 29607, United States
Research Site
Germantown, Tennessee, 38138, United States
Research Site
Nashville, Tennessee, 037214, United States
Research Site
Dallas, Texas, 75246, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Richmond, Virginia, 23298, United States
Research Site
Seattle, Washington, 98915, United States
Research Site
Milwaukee, Wisconsin, 53226, United States
Research Site
Vancouver, British Columbia, V5Z 1M9, Canada
Research Site
Vancouver, British Columbia, V6Z 1Y6, Canada
Research Site
Halifax, Nova Scotia, B3RIV9, Canada
Research Site
London, Ontario, N6A 5A5, Canada
Research Site
Toronto, Ontario, M2J 4W8, Canada
Research Site
Montreal, Quebec, H2X 0A9, Canada
Research Site
Rimouski, Quebec, G5L 5T1, Canada
Research Site
Hefei, Anhui, 230001, China
Research Site
Beijing, Beijing Municipality, 100029, China
Research Site
Beijing, Beijing Municipality, 100034, China
Research Site
Beijing, Beijing Municipality, 100191, China
Research Site
Beijing, Beijing Municipality, 100730, China
Research Site
Chongqing, Chongqing Municipality, 400000, China
Research Site
Fuzhou, Fujian, 350005, China
Research Site
Xiamen, Fujian, 361016, China
Research Site
Guangzhou, Guangdong, 510080, China
Research Site
Guangzhou, Guangdong, 510515, China
Research Site
Guiyang, Guizhou, 550004, China
Research Site
Shijiazhuang, Hebei, 050000, China
Research Site
Wuhan, Hubei, 430000, China
Research Site
Wuhan, Hubei, 430030, China
Research Site
Changsha, Hunan, 410011, China
Research Site
Changsha, Hunan, 410013, China
Research Site
Nanjing, Jiangsu, 210029, China
Research Site
Suzhou, Jiangsu, 215006, China
Research Site
Nanchang, Jiangxi, 330000, China
Research Site
Dalian, Liaoning, 116011, China
Research Site
Jinan, Shandong, 250012, China
Research Site
Shanghai, Shanghai Municipality, 200025, China
Research Site
Shanghai, Shanghai Municipality, 200031, China
Research Site
Shanghai, Shanghai Municipality, 200040, China
Research Site
Taiyuan, Shanxi, 030001, China
Research Site
Chengdu, Sichuan, 610041, China
Research Site
Chengdu, Sichuan, 610072, China
Research Site
Shaanxi, Xi'An, 710061, China
Research Site
Hangzhou, Zhejiang, 310009, China
Research Site
Würzburg, Bavaria, DE-97072, Germany
Research Site
Frankfurt am Main, Hesse, 60590, Germany
Research Site
Hanover, Lower Saxony, 30625, Germany
Research Site
Aachen, North Rhine-Westphalia, 52074, Germany
Research Site
Cologne, North Rhine-Westphalia, 50937, Germany
Research Site
Mainz, Rhineland-Palatinate, 55131, Germany
Research Site
Homburg, Saarland, 66421, Germany
Research Site
Berlin, 10117, Germany
Research Site
Huelva, Andalusia, 21005, Spain
Research Site
Bilbao, Basque Country, 48013, Spain
Research Site
Las Palmas de Gran Canaria, Canary Islands, 35010, Spain
Research Site
Salamanca, Castille and León, 37007, Spain
Research Site
Barcelona, Catalu A, 08035, Spain
Research Site
Barcelona, Catalu A, 8036, Spain
Research Site
Cataluna, Catalu A, 08907, Spain
Research Site
Majadahonda, Madrid, 28222, Spain
Research Site
Islas Baleares, Palma de Mallorca, 07198, Spain
Research Site
Birmingham, West Midlands, B15 2GW, United Kingdom
Research Site
Glasgow, G51 4TF, United Kingdom
Research Site
London, NW3 2QG, United Kingdom
Study Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 23, 2026
Record last verified: 2026-09
Plan to share only the redacted CSR synopsis
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: